Made up of an exciting team of multinational researchers, the Black Swan Research Initiative®  team has developed a way to monitor the status of myeloma at very low levels, or minimal residual disease (MRD). By developing accurate testing to identify MRD, treatment efforts to rid the body of the disease entirely can be enhanced. During 2016, the Black Swan team developed such a test, known as Next Generation Flow. In this video, Dr. Brian Durie reveals where NGF stands today worldwide, and also discusses other key BSRI team projects, including iStopMM and the ASCENT trial. 

 

Previous Post
Do lytic lesions in the spine ever go away?
Next Post
Global Collaboration Essential to Achieve a Cure for Myeloma

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.